)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Biomea Fusion
Biomea Fusion (BMEA) investor relations material
Biomea Fusion H.C. Wainwright 28th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 28th Annual Global Investment Conference summary15 Sep, 2026
Strategic focus and leadership
Focused on two main assets: a first-in-class beta cell restorative therapy and a next-generation GLP-1 agent.
Leadership team is experienced with a clear vision and execution plan.
Company has a cash runway through key upcoming inflection points.
Scientific innovation and clinical progress
First menin inhibitor targeting diabetes, aiming to restore pancreatic beta cells rather than just lowering blood sugar.
Preclinical and clinical data show significant C-peptide increases and beta cell mass growth in Type 1 diabetes.
Combination of menin inhibitor with GLP-1 agonist in obesity shows muscle preservation, additional weight loss, and health benefits.
Phase II studies in Type 1 and Type 2 diabetes are ongoing, with key readouts expected by end of next year.
Market opportunity and differentiation
Diabetes and obesity represent large, underserved markets with current therapies only addressing symptoms.
Menin inhibition offers a novel approach by restoring beta cell function, potentially delaying or avoiding insulin dependence.
Next-generation GLP-1 (BMF-650) aims to improve tolerability and patient persistence compared to current GLP-1 drugs.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Biomea Fusion
- Novel oral therapies show promise for diabetes and obesity with key Phase II data ahead.BMEA
Corporate presentation - Icovamenib and BMF-650 show promise for durable diabetes and obesity treatment innovation.BMEACorporate presentation
- Net loss narrowed, but liquidity concerns persist as cash runway extends only into Q2 2027.BMEAQ2 2026
- Promising diabetes therapies advance with pivotal data and partnership-driven development ahead.BMEAPiper Sandler 37th Annual Healthcare Conference
- Directors and auditors were approved by majority vote, with results to be filed with the SEC.BMEAAGM 2026
- Phase II diabetes and obesity trials advance, with key data expected in the next 12 months.BMEAJefferies Global Healthcare Conference 2026
- Icovamenib and BMF-650 show promise for durable diabetes and obesity treatment breakthroughs.BMEACorporate presentation
- Icovamenib achieved robust HbA1c reduction and strong safety in insulin-deficient type 2 diabetes.BMEAStudy Result
- BMF-500 demonstrated early efficacy and strong safety in relapsed/refractory acute leukemia.BMEAStudy Update
Next Biomea Fusion earnings date
Q3 202630 Oct, 2026
Biomea Fusion
Next Biomea Fusion earnings date
Q3 202630 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage